---
title: "ADC Therapeutics grants new employee options for 17,000 shares under inducement plan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291456612.md"
description: "ADC Therapeutics granted options to purchase 17,000 common shares to a new employee on July 1, 2026, under its inducement plan. The vesting schedule stipulates that 25% of the shares will vest on the first anniversary, with the remaining balance vesting monthly over the subsequent 36 months. Full vesting is achieved on the fourth anniversary, contingent upon continued employment."
datetime: "2026-07-01T20:07:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291456612.md)
  - [en](https://longbridge.com/en/news/291456612.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291456612.md)
---

# ADC Therapeutics grants new employee options for 17,000 shares under inducement plan

-   ADC Therapeutics granted options to buy 17,000 common shares to a new employee on July 1, 2026. \* Vesting schedule: 25% on the first anniversary; remaining balance vests monthly over the next 36 months. \* Full vesting occurs on the fourth anniversary, subject to continued employment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: NY96616) on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ADCT.US](https://longbridge.com/en/quote/ADCT.US.md)

## Related News & Research

- [ADC Therapeutics completes LOTIS-7 Phase 1b enrollment for Zynlonta-glofitamab combo in r/r DLBCL](https://longbridge.com/en/news/291272696.md)
- [ADC Therapeutics reports positive LOTIS-5 PFS results; plans pre-sBLA meeting and Q4 2026 sBLA](https://longbridge.com/en/news/288624565.md)
- [Analyst Backs Crescent Biopharma With Buy Rating on Advancing ADC Pipeline and Strong Cash Runway](https://longbridge.com/en/news/294417283.md)
- [IWM Long Strangle Benefits from Large Stock Price Moves](https://longbridge.com/en/news/293767641.md)
- [Adlai Nortye Initiated With Buy on Differentiated RAS-Targeting Pipeline, ADC Strategy and Solid Cash Runway](https://longbridge.com/en/news/293951548.md)